| Name | Theracryf |
|---|---|
| Epic | TCF |
| Isin | GB00BSVYN304 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 0.88p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £3.76 | Debt ratio | n/a |
| Shares in issue | 429.62 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | n/a |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -1.14 | 52-week high / low | 0.53p / 1.85p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Theracryf |
|---|---|
| Address | Liverpool Science Park Innovation Centre 2, 146 Brownlow Hill, Liverpool, Merseyside, United Kingdom, L3 5RF |
| Telephone | |
| Website | http://www.theracryf.com/ |
| Director | Position |
|---|---|
| Dr Huw Jones | CEO |
| Mr Toni Hänninen | CFO |
| Dr Susan (Sue) Foden | Interim Chairman |
| Dr Alan Barge | Independent Non-Executive Director |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/03/24 | 31/03/23 | 31/03/22 |
| Intangible asssets and goodwill | 0.03 | 0.04 | 0.05 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 0.03 | 0.05 | 0.06 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 1.02 | 1.13 | 0.55 |
| Cash and equivalents | 2 | 5 | 4.51 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 3.06 | 6.17 | 9.64 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 0.72 | 0.83 | 0.41 |
| Long term liabilities | n/a | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.72 | 0.83 | 0.41 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 2.34 | 5.34 | 9.23 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 0.69 | 0.69 | 0.69 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -28.92 | -25.79 | -21.89 |
| Share premium account | 27.87 | 27.87 | 27.87 |
| Total equity | 2.34 | 5.34 | 9.23 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -3.57 | -5.1 | -3.19 |
| Pre-tax profit | -3.57 | -5.01 | -3.17 |